Modified CAR-T Cell Therapy Shows Promising HIV Suppression in Early Trial
Similar Articles
New Drugs Target 'Zombie' Cells to Combat Cancer and Aging
Lab-Grown Insulin-Producing Cells Restore Blood Sugar Control in Diabetic Mice
New Imaging Technique Reveals Immune Cell Killing Machinery
Pre-Surgery Immunotherapy Shows Promise for a Subtype of Colorectal Cancer
Pancreatic Cancer Survival Advances Through New Drugs and Vaccines
Researchers have reported that a modified version of CAR-T cell therapy, a cancer treatment, strongly suppressed HIV in two patients for extended periods without their usual medicines. The early-stage experiment, led by Dr. Steven Deeks of UCSF, tested genetically engineered immune cells designed to hunt HIV and resist infection. While the response was not universal, the findings suggest a potential new avenue for long-term HIV control.
Facts First
- A single dose of modified CAR-T cells suppressed HIV in two patients for nearly one and two years without their usual antiretroviral medicines.
- The therapy involves engineering a patient's own T cells to both find and kill HIV-infected cells and resist infection by the virus itself.
- No serious side effects were reported in the early-stage experiment, which tested different dosing strategies.
- The response was not universal; three other participants in the trial showed no sustained suppression and resumed their regular HIV treatment.
- The research is funded by amfAR, The Foundation for AIDS Research, which is supporting work to create easier-to-use versions of such therapies.
What Happened
Researchers led by Dr. Steven Deeks of the University of California, San Francisco (UCSF) reported that a modified CAR-T cell therapy strongly suppressed HIV in two patients. In the early-stage experiment, participants stopped their standard HIV medicines on the day they received an infusion of their own genetically engineered T cells. Two of six patients who also received a small amount of chemotherapy saw their HIV levels drop to undetectable levels for nearly one and two years, respectively, with occasional viral increases that may indicate the CAR-T cells were actively fighting the virus. A third patient in this group had a temporary response before resuming regular treatment. The first three recipients of the therapy, who did not receive the preparatory chemotherapy, showed no response.
Why this Matters to You
If you or someone you know lives with HIV, this research represents a step toward a potential future where long-term viral suppression might be achieved with a single treatment, rather than daily medication. While current HIV medicines are highly effective at controlling the virus, they require lifelong adherence and do not eliminate the virus from the body. A therapy that could provide sustained remission could significantly improve quality of life and reduce the burden of daily treatment. For the nearly 40 million people living with HIV globally, advances like this may eventually offer more options for managing the condition.
What's Next
The research data is being presented at a meeting of the American Society of Gene and Cell Therapy, which will allow the scientific community to review the findings. Further research will be needed to understand why the therapy worked dramatically in some patients but not in others; Dr. Deeks noted that the three patients who did not have a sustained response had all started their original HIV treatment soon after infection. Work funded by amfAR, The Foundation for AIDS Research, is already underway to create easier-to-use versions of such therapies, which could make them more accessible if future trials confirm their safety and efficacy.